UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 277

Sortiert nach

Multicenter, Randomized, Open-Label, Phase III Trial of Decitabine Versus Patient Choice, With Physician Advice, of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia

Journal of clinical oncology, 2012-07, Vol.30 (21), p.2670-2677

2012

Volltextzugriff (PDF)

Alemtuzumab Compared With Chlorambucil As First-Line Therapy for Chronic Lymphocytic Leukemia

Journal of clinical oncology, 2007-12, Vol.25 (35), p.5616-5623

2007

Volltextzugriff (PDF)

Rituximab Plus Fludarabine and Cyclophosphamide Prolongs Progression-Free Survival Compared With Fludarabine and Cyclophosphamide Alone in Previously Treated Chronic Lymphocytic Leukemia

Journal of clinical oncology, 2010-04, Vol.28 (10), p.1756-1765

2010

Volltextzugriff (PDF)

Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma

The New England journal of medicine, 2008-08, Vol.359 (9), p.906-917

2008

Volltextzugriff (PDF)

Phase III Study of R-CVP Compared With Cyclophosphamide, Vincristine, and Prednisone Alone in Patients With Previously Untreated Advanced Follicular Lymphoma

Journal of clinical oncology, 2008-10, Vol.26 (28), p.4579-4586

2008

Volltextzugriff (PDF)

Bortezomib Plus Melphalan and Prednisone Compared With Melphalan and Prednisone in Previously Untreated Multiple Myeloma: Updated Follow-Up and Impact of Subsequent Therapy in the Phase III VISTA Trial

Journal of clinical oncology, 2010-05, Vol.28 (13), p.2259-2266

2010

Volltextzugriff (PDF)

Randomized Phase III Study of Pegylated Liposomal Doxorubicin Plus Bortezomib Compared With Bortezomib Alone in Relapsed or Refractory Multiple Myeloma: Combination Therapy Improves Time to Progression

Journal of clinical oncology, 2007-09, Vol.25 (25), p.3892-3901

2007

Volltextzugriff (PDF)

The VEGF receptor, neuropilin‐1, represents a promising novel target for chronic lymphocytic leukemia patients

International journal of cancer, 2013-09, Vol.133 (6), p.1489-1496

2013

Volltextzugriff (PDF)

Safety of bosutinib versus imatinib in the phase 3 BELA trial in newly diagnosed chronic phase chronic myeloid leukemia

American journal of hematology, 2014-10, Vol.89 (10), p.947-953

2014

Volltextzugriff (PDF)

Programmed death-1 and its ligand are novel immunotolerant molecules expressed on leukemic B cells in chronic lymphocytic leukemia

PloS one, 2012-04, Vol.7 (4), p.e35178-e35178

2012

Volltextzugriff (PDF)

Randomized Phase II Study of Bortezomib, Thalidomide, and Dexamethasone With or Without Cyclophosphamide As Induction Therapy in Previously Untreated Multiple Myeloma

Journal of clinical oncology, 2013-01, Vol.31 (2), p.247-255

2013

Volltextzugriff (PDF)

Metformin - its potential anti-cancer and anti-aging effects

Postȩpy higieny i medycyny doświadczalnej, 2017-03, Vol.71 (1), p.170-175

2017

Volltextzugriff (PDF)

The function of a novel immunophenotype candidate molecule PD-1 in chronic lymphocytic leukemia

Leukemia & lymphoma, 2015-10, Vol.56 (10), p.2908-2913

2015

Volltextzugriff (PDF)

Effect of FCGR2A and FCGR3A variants on CLL outcome

Blood, 2010-11, Vol.116 (20), p.4212-4222

2010

Volltextzugriff (PDF)

Efficacy, safety and pharmacokinetic profiles of a plasma-derived VWF/FVIII concentrate (VONCENTO®) in subjects with haemophilia A (SWIFT-HA study)

Thrombosis research, 2016-01, Vol.137, p.119-125

2016

Volltextzugriff (PDF)

Real‑life experience with bortezomib‑based regimens in elderly patients with newly diagnosed multiple myeloma and comorbidities: a Polish retrospective multicenter study

Polskie archiwum medycyny wewne̦trznej, 2017-11, Vol.127 (11), p.765-774

2017

Volltextzugriff (PDF)

Th17/IL-17A might play a protective role in chronic lymphocytic leukemia immunity

PloS one, 2013-11, Vol.8 (11), p.e78091

2013

Volltextzugriff (PDF)

Cytotoxic activity of valproic acid on primary chronic lymphocytic leukemia cells

Advances in clinical and experimental medicine : official organ Wroclaw Medical University, 2015-01, Vol.24 (1), p.55-62

2015

Volltextzugriff (PDF)

Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma

The New England journal of medicine, 2007-11, Vol.357 (21), p.2123-2132

2007

Volltextzugriff (PDF)

1 – 25 von 277

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(261)
Mit Volltextzugriff
(250)

Publikationsform

Artikel
(276)
Berichte
(1)

Sprache

Englisch
(251)
Polnisch
(25)
Japanisch
(10)
Russisch
(4)

Erscheinungsjahr

n.n

Thema

Humans
(144)
Science & Technology
(135)
Life Sciences & Biomedicine
(132)
Female
(112)
Male
(112)
Middle Aged
(101)
Aged
(87)
Adult
(85)
Hematology
(66)
Oncology
(52)
Aged, 80 And Over
(47)
Multiple Myeloma
(38)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(36)
Biological And Medical Sciences
(33)
Medical Sciences
(33)
Treatment Outcome
(32)
Apoptosis
(25)
Leukemia, Lymphocytic, Chronic, B-Cell - Drug Therapy
(24)
Hematologic And Hematopoietic Diseases
(23)
Disease-Free Survival
(22)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Multicenter, Randomized, Open-Label, Phase III Trial of Decitabine Versus Patient Choice, With Physician Advice, of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia

Alemtuzumab Compared With Chlorambucil As First-Line Therapy for Chronic Lymphocytic Leukemia

Rituximab Plus Fludarabine and Cyclophosphamide Prolongs Progression-Free Survival Compared With Fludarabine and Cyclophosphamide Alone in Previously Treated Chronic Lymphocytic Leukemia

Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma

Phase III Study of R-CVP Compared With Cyclophosphamide, Vincristine, and Prednisone Alone in Patients With Previously Untreated Advanced Follicular Lymphoma

Persistent Overall Survival Benefit and No Increased Risk of Second Malignancies With Bortezomib-Melphalan-Prednisone Versus Melphalan-Prednisone in Patients With Previously Untreated Multiple Myeloma

Cladribine, But Not Fludarabine, Added to Daunorubicin and Cytarabine During Induction Prolongs Survival of Patients With Acute Myeloid Leukemia: A Multicenter, Randomized Phase III Study

Bortezomib Plus Melphalan and Prednisone Compared With Melphalan and Prednisone in Previously Untreated Multiple Myeloma: Updated Follow-Up and Impact of Subsequent Therapy in the Phase III VISTA Trial

Randomized Phase III Study of Pegylated Liposomal Doxorubicin Plus Bortezomib Compared With Bortezomib Alone in Relapsed or Refractory Multiple Myeloma: Combination Therapy Improves Time to Progression

The VEGF receptor, neuropilin‐1, represents a promising novel target for chronic lymphocytic leukemia patients

Safety of bosutinib versus imatinib in the phase 3 BELA trial in newly diagnosed chronic phase chronic myeloid leukemia

Programmed death-1 and its ligand are novel immunotolerant molecules expressed on leukemic B cells in chronic lymphocytic leukemia

Randomized Phase II Study of Bortezomib, Thalidomide, and Dexamethasone With or Without Cyclophosphamide As Induction Therapy in Previously Untreated Multiple Myeloma

Metformin - its potential anti-cancer and anti-aging effects

Comparison of Cladribine Plus Cyclophosphamide With Fludarabine Plus Cyclophosphamide As First-Line Therapy for Chronic Lymphocytic Leukemia: A Phase III Randomized Study by the Polish Adult Leukemia Group (PALG-CLL3 Study)

The function of a novel immunophenotype candidate molecule PD-1 in chronic lymphocytic leukemia

Stem cell mobilization in multiple myeloma patients relapsing after previous autologous hematopoietic stem cell transplantation: A multicenter report by the Polish Myeloma Study Group

Effect of FCGR2A and FCGR3A variants on CLL outcome

Efficacy, safety and pharmacokinetic profiles of a plasma-derived VWF/FVIII concentrate (VONCENTO®) in subjects with haemophilia A (SWIFT-HA study)

Real‑life experience with bortezomib‑based regimens in elderly patients with newly diagnosed multiple myeloma and comorbidities: a Polish retrospective multicenter study

High efficacy and safety of VTD as an induction protocol in patients with newly diagnosed multiple myeloma eligible for high dose therapy and autologous stem cell transplantation: A report of the Polish Myeloma Study Group

Cladribine with prednisone versus chlorambucil with prednisone as first-line therapy in chronic lymphocytic leukemia: report of a prospective, randomized, multicenter trial

Th17/IL-17A might play a protective role in chronic lymphocytic leukemia immunity

Cytotoxic activity of valproic acid on primary chronic lymphocytic leukemia cells

Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma

Suchergebnisse filtern